Biotech: Page 22
-
Courtesy of GSK
GSK leans on Flagship for help finding new drugs, vaccines
The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.
By Gwendolyn Wu • July 29, 2024 -
Doucefleur via Getty Images
Ventyx’s TYK2 drug suffers second setback
The company claimed “higher than anticipated” scores from trial volunteers on placebo led to the disappointing data, prompting it to halt internal trials.
By Jonathan Gardner • July 29, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
DNY59 via Getty Images
NewAmsterdam heart drug hits trial goal, but data appear to disappoint investors
The study is the latest test of a class of cholesterol medicines known as CETP inhibitors, which were abandoned by several large drugmakers last decade.
By Ben Fidler • July 29, 2024 -
Daniel Tadevosyan via Getty Images
Two biotechs cut staff; AbbVie weathers biosimilar threat
Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs.
By BioPharma Dive staff • July 26, 2024 -
Elizabeth Regan/BioPharma Dive
Viking shares jump on plans to speed obesity drug into late-stage testing
The drug’s advancement continued what one analyst described as a “torrid” pace for Viking’s closely watched medicine, which started human testing in 2022 and could reach a Phase 3 trial next year.
By Kristin Jensen • July 25, 2024 -
Permission granted by Biogen
Biogen, Sage tremor drug fails key trial
Known as SAGE-324, the drug was one of the key assets Biogen gained rights to through a billion-dollar research deal inked back in 2020.
By Jacob Bell • July 24, 2024 -
Daniel Tadevosyan via Getty Images
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.
By BioPharma Dive staff • July 24, 2024 -
Naeblys via Getty Images
Autobahn raises $100M on investor interest in neuropsych drugs
Autobahn’s lead candidate is designed to stimulate thyroid hormone receptors as a way to complement existing antidepressants.
By Gwendolyn Wu • July 24, 2024 -
Peddalanka Ramesh Babu via Getty Images
Startup led by former J&J executives raises $165M for cancer, immune disease drugs
Peter Lebowitz, who for years led J&J’s oncology R&D, is the CEO of the startup, called Third Arc Bio and launched by Omega Funds in 2022.
By Ned Pagliarulo • July 23, 2024 -
Permission granted by Bluebird bio
US government declines to clear Bluebird fertility support for Zynteglo patients
The Health and Human Services' inspector general issued a "negative opinion" on Bluebird's request one week after Vertex sued the federal government over access to fertility preservation services.
By Ned Pagliarulo • July 22, 2024 -
Brian Tucker/BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 22, 2024 -
Permission granted by InterVenn Biosciences
Sponsored by InterVenn BiosciencesBreakthroughs in immunotherapy: glycoproteins as predictive biomarkers for therapeutic response
Serum-based glycoproteins demonstrate success in predicting immune checkpoint inhibitor therapy outcomes.
July 22, 2024 -
Daniel Tadevosyan via Getty Images
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
By BioPharma Dive staff • July 19, 2024 -
Marcin Klapczynski via Getty Images
Immune resetArtiva prices $167M IPO, riding optimism for autoimmune cell therapy
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
By Ben Fidler • July 18, 2024 -
Daniel Tadevosyan via Getty Images
Caribou lays off staff; Roche walks away from Relay
Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan.
By BioPharma Dive staff • July 17, 2024 -
Stadtratte via Getty Images
NGM, now private, raises $122M for redrawn research plans
The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.
By Delilah Alvarado • July 17, 2024 -
Jolygon via Getty Images
Cardurion raises another $260M to fuel heart drug pipeline
The financing, which ranks as one of the year’s larger private rounds, will help the startup advance a pair of drugs and potentially acquire other medicines.
By Jonathan Gardner • July 16, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex taps Orum to hunt for better ‘preconditioning’ drugs
The deal gives Vertex rights to use Orum’s ADC-like technology to discover gentler preparatory regimens for patients receiving intensive treatments like Casgevy.
By Gwendolyn Wu • July 16, 2024 -
Permission granted by Sionna Therapeutics
Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex
The startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.
By Ben Fidler • July 16, 2024 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Asceneuron raises another $100M for Alzheimer’s drug development
The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has intrigued both healthcare investors and pharma venture arms.
By Jacob Bell • July 16, 2024 -
OGphoto via Getty Images
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
By Ned Pagliarulo • July 15, 2024 -
Daniel Tadevosyan via Getty Images
Leqembi sales inch higher; Spark’s pivot leads to layoffs
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, a well-funded DNA sequencing startup landed one of the year’s larger private funding rounds.
By BioPharma Dive staff • July 12, 2024 -
Daniel Tadevosyan via Getty Images
AbbVie names new R&D head; Arcutis eczema cream approved
Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.
By BioPharma Dive staff • July 10, 2024 -
Jerod Harris via Getty Images
Flagship raises $3.6B for biotech investing
The latest round of funding comes as the biotech company creator adds executives and prepares to grow more life sciences startups.
By Kristin Jensen • July 10, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.
By Jacob Bell • July 10, 2024
Previous
